Neo Ivy Capital Management Kymera Therapeutics, Inc. Transaction History
Neo Ivy Capital Management
- $293 Million
- Q1 2025
A detailed history of Neo Ivy Capital Management transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Neo Ivy Capital Management holds 14,420 shares of KYMR stock, worth $484,223. This represents 0.13% of its overall portfolio holdings.
Number of Shares
14,420Holding current value
$484,223% of portfolio
0.13%Shares
1 transactions
Others Institutions Holding KYMR
# of Institutions
188Shares Held
60.1MCall Options Held
49.6KPut Options Held
17K-
Price T Rowe Associates Inc Baltimore, MD6.87MShares$231 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$201 Million2.67% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$173 Million7.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.15MShares$173 Million3.02% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$164 Million32.49% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $1.84B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...